LC-MS/MS-based serum proteomics reveals a distinctive signature in a rheumatoid arthritis mouse model after treatment with mesenchymal stem cells
Fig 2
Effects of repeated injection of hUCB-MSCs in type II CIA model.
(A) Representative images show gross features of front and hind paws at 44 days after immunization for all three animal groups. (B) Clinical scores of arthritic symptoms assessed by a visual arthritis scoring system were plotted daily until 44 days (n = 4 for each group). (C) Incidence rates of vehicle CS10 and hUCB-MSCs treated mice were plotted daily until 44 days (n = 4). Each point on the graph is presented as mean ± SD. Normality tests were performed using the Shapiro-Wilk normality test. Statistical significance versus vehicle CS10-treated CIA control group (as a control group) was determined by Kruskal-Wallis test with Dunn’s multiple comparisons test (** p < 0.01).